Evaluation of an Analgosedation Protocol in Mechanically Ventilated Patients

Tampa General Hospital1 site in 1 countrySeptember 13, 2019

ConditionsEffect of Protocolized Sedation on Days of Mechanical Ventilation in the ICU

Overview

Phase: N/A
Intervention: Not specified
Conditions: Effect of Protocolized Sedation on Days of Mechanical Ventilation in the ICU
Sponsor: Tampa General Hospital
Locations: 1
Primary Endpoint: Days on mechanical ventilation
Status: Withdrawn
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate how the investigators provide sedation (medicine that make you sleepy) in the investigators intensive care unit (ICU). This study will look at a new way of using sedation in the ICU to see what effect it has on patients and if it decreases the amount of time spent on mechanical ventilation (machine that breathes for you), and in the ICU.

Registry

clinicaltrials.gov

Start Date

September 13, 2019

End Date

April 2021

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Tampa General Hospital

Responsible Party

Principal Investigator

Beatrice Adams

Pharmacotherapy Specialist

Tampa General Hospital

Eligibility Criteria

Inclusion Criteria

•Patients 18 years of age and older
•Patients expected to require mechanical ventilation for greater than 48 hrs

Exclusion Criteria

•Need for continuous neuromuscular blockade
•Severe chronic neurocognitive dysfunction
•Tracheostomy at the time of study enrollment
•Alcohol withdrawal risk or symptoms
•Drug overdose
•Chronic use of narcotics
•Active seizures

Outcomes

Primary Outcomes

Days on mechanical ventilation

Time Frame: Participants will be assessed daily for the duration of their stay in the ICU, an expected average of 4-5 days

Secondary Outcomes

ICU Length of stay(Participants will be followed for the entire length of their ICU stay, expected average of 4-7 days)
28 day mortality(Participants will be followed for 28 days from enrollment into the study)